CD86 and autoimmune thrombocytopenic purpura: In a preclinical study by Yu et al. 2021, the expression of CD69 and the BCR signaling pathway CD86 was significantly reduced with orelabrutinib in polymorphonuclear cells separated from ITP and healthy human subjects.